For Q4 2025, PTC Therapeutics generated total revenues of 164677000 dollars, reflecting lower collaboration revenue and a significant Translarna France adjustment. The company reported a net loss of 134965000 dollars and a loss from operations of 71349000 dollars, while maintaining a strong cash position of 1945371000 dollars at year end.

PTC Therapeutics experienced a decline in total revenue to $178.9 million in Q2 2025 compared to the previous year, primarily due to reduced net product sales of Translarna and Emflaza. However, the company significantly narrowed its net loss to $64.8 million and reported strong cash and cash equivalents, bolstered by the recent approvals and global launch of Sephience™.

PTC Therapeutics reported a total net product and royalty revenue of $190 million for the first quarter of 2025. The company also announced a positive CHMP opinion for Sephience and progress in its global launch activities, maintaining a strong cash position of over $2.0 billion.

PTC Therapeutics reported total Q4 2024 revenue of $213 million, driven by solid product sales and royalty revenue. The company's net loss for the quarter was $65.9 million, showing improvement from the prior year. PTC successfully met all clinical and regulatory milestones in 2024 and maintains a strong cash position exceeding $1.1 billion.

PTC Therapeutics announced a strong start to 2024, with total revenues of $210.1 million for the first quarter, driven by solid commercial performance and the achievement of key clinical and regulatory milestones, including the submission of the MAA for sepiapterin and the BLA for Upstaza.

PTC Therapeutics announced its Q4 and full-year 2023 financial results, reporting a Q4 total revenue of $307.1 million compared to $167.4 million for the same period in 2022. The company's full-year revenue reached $937.8 million, a 34% increase year-over-year. Key milestones include advancements in regulatory submissions for sepiapterin and vatiquinone, as well as updates on clinical trials for PTC518 and utreloxastat.

PTC Therapeutics reported total revenues of $196.6 million for the third quarter of 2023. The company finalized a strategic partnership with Royalty Pharma, strengthening its financial position. PTC is progressing with regulatory submissions for its pipeline programs, including sepiapterin in PKU, and continues enrollment in the PIVOT-HD study for PTC518 for Huntington’s disease.

PTC Therapeutics reported a 29% year-over-year revenue growth in the second quarter of 2023, with total revenue reaching $213.8 million. The company saw positive data readouts from APHENITY and PIVOT-HD trials and anticipates several regulatory submissions in the second half of the year.

PTC Therapeutics reported a total revenue of $220.4 million for Q1 2023, a 48% increase compared to Q1 2022. The company is progressing with clinical studies and anticipates readouts from four clinical studies in the second quarter of 2023.

PTC Therapeutics reported total revenues of $167.4 million for the fourth quarter of 2022, compared to $165.2 million for the fourth quarter of 2021. The company's total revenues for the full year 2022 were $698.8 million, compared to $538.6 million for the full year 2021. PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion.

PTC Therapeutics announced a 57% year-over-year increase in total quarterly revenue, reaching $217 million. The company also increased its 2022 DMD revenue guidance and total revenue guidance, secured strategic financing with Blackstone, and continued to advance its pipeline of innovative compounds in clinical development.

PTC Therapeutics reported a total revenue of $165.5 million for the second quarter of 2022, representing a 42% year-over-year growth. The company's Duchenne muscular dystrophy (DMD) franchise continued to show strong growth. Upstaza™ gene therapy was granted marketing authorization by the European Commission for the treatment of AADC deficiency.

PTC Therapeutics announced its Q1 2022 financial results, highlighted by a 26% year-over-year revenue increase to $148.7 million. The DMD franchise and Evrysdi royalties drove revenue growth. The company is advancing its clinical pipeline with the initiation of a Phase 2 trial for Huntington's disease and expects a CHMP opinion on its AADC gene therapy soon.

PTC Therapeutics announced Q4 and full year 2021 financial results, marked by a 41% year-over-year revenue growth. The company's total revenues for Q4 2021 reached $165.2 million, compared to $118.9 million in Q4 2020. Full year 2021 total revenues were $538.6 million, up from $380.8 million in 2020. The company reaffirmed its 2022 total revenue guidance of $700-750 million.

PTC Therapeutics announced its Q3 2021 financial results, with total revenues of $138.7 million, a 17% increase compared to Q3 2020. The company also raised its 2021 DMD franchise revenue guidance to $400-$420 million. APHENITY Phase 3 trial of PTC923 in phenylketonuria (PKU) was initiated.

PTC Therapeutics reported a strong second quarter in 2021, with a 55% increase in total revenue compared to the same period in 2020, reaching $116.7 million. The Duchenne muscular dystrophy (DMD) franchise was a key driver, with $102 million in net product revenue, a 36% increase year-over-year. The company also raised its 2021 DMD franchise revenue guidance to $370-$390 million. Additionally, the company has multiple ongoing clinical trials, three of which are registration-directed clinical studies.

PTC Therapeutics announced a strong first quarter with total revenue of $117.9 million, a 73% increase over Q1 2020. The DMD franchise contributed $90 million, driven by Translarna and Emflaza. The company also highlighted positive preliminary results in the PTC518 Huntington’s disease program.

PTC Therapeutics reported total revenues of $118.9 million for the fourth quarter of 2020, compared to $96.5 million for the fourth quarter of 2019. Total revenues were $380.8 million for the full year 2020, compared to $307.0 million for the full year 2019. Net loss was $74.4 million for the fourth quarter of 2020, compared to net loss of $77.7 million for the fourth quarter of 2019.

PTC Therapeutics reported a strong third quarter with total revenue of $118.4 million, a 66% increase year-over-year. The growth was driven by the U.S. launch of Evrysdi and continued growth in the Duchenne muscular dystrophy franchise. The company also initiated a registration-directed trial for mitochondrial epilepsy.

PTC Therapeutics reported total net product revenues of $75.2 million for the second quarter of 2020. The company's Duchenne muscular dystrophy franchise performed strongly, with Emflaza increasing 30% year-over-year. PTC is advancing its pipeline and platforms with the acquisition of a late-stage asset for phenylketonuria (PKU).

PTC Therapeutics reported a 27% year-over-year revenue growth in Q1 2020, reaching $68.3 million. The company highlighted the growth of its DMD franchise and positive results from risdiplam clinical trials. Due to the uncertainty of the duration and severity of the COVID-19 impact, PTC withdrew financial guidance for the 2020 fiscal year.

PTC Therapeutics reported total revenues of $96.5 million for Q4 2019, compared to $86.3 million for Q4 2018. The company's net loss was $77.7 million for the quarter, compared to a net loss of $48.3 million for the same period in the previous year. The company reaffirms full year 2020 guidance.